Literature DB >> 18813109

PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.

Weigang Wang1, Katie Carper, Frances Malone, Yvette Latchman, James Perkins, Yaowen Fu, Jorge Reyes, Wei Li.   

Abstract

BACKGROUND: PD-L1, a ligand for programmed death 1 (PD-1), delivers a negative costimulatory signal to T cells and plays a critical role in the regulation of peripheral tolerance.
METHODS: We used PD-L1(-/-) mice to evaluate the role of the PD-L1 signal on allogeneic immune responses in vivo and the underlying mechanisms. Heart transplantation was performed from PD-L1(-/-) donors or recipients in major histocompatibility complex fully mismatched mouse combinations. The immunologic function of allograft recipients was evaluated ex vivo by enzyme-linked immunospot, mixed lymphocytes reaction, cytotoxic T lymphocyte, and flow cytometry.
RESULTS: Our results demonstrated that PD-L1(-/-) T cells proliferated vigorously under alloantigen stimulation, and also that the antigen-presenting cells (APCs) from PD-L1(-/-) mice exhibited a stronger allostimulatory activity compared with that in wild-type mice. Heart allografts were rejected at an accelerated rate in both PD-L1(-/-) donors and recipients. This was associated with significantly augmented donor specific T-cell proliferation and antidonor cytotoxic T lymphocyte activities, and enhanced Th1- or Th2-type immune responses of heart allograft recipients.
CONCLUSIONS: Absence of PD-L1 input triggers a stimulatory signal to effector T cells and APCs, accelerating heart allograft rejection. Engagement of the PD-L1 signal on T cells or APCs may be necessary to induce transplant tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813109     DOI: 10.1097/TP.0b013e3181861932

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts.

Authors:  Cheguevara Afaneh; Thangamani Muthukumar; Michelle Lubetzky; Ruchuang Ding; Catherine Snopkowski; Vijay K Sharma; Surya Seshan; Darshana Dadhania; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

2.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

3.  The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.

Authors:  Francesca D'Addio; Leonardo V Riella; Bechara G Mfarrej; Lola Chabtini; La Tonya Adams; Melissa Yeung; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Indira Guleria
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

4.  The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Authors:  Govindarajan Thangavelu; Kenneth M Murphy; Hideo Yagita; Louis Boon; Colin C Anderson
Journal:  Immunobiology       Date:  2011-01-12       Impact factor: 3.144

Review 5.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

6.  PD-1 regulates T cell proliferation in a tissue and subset-specific manner during normal mouse pregnancy.

Authors:  Michelle T Shepard; Elizabeth A Bonney
Journal:  Immunol Invest       Date:  2013-06-19       Impact factor: 3.657

7.  Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.

Authors:  Babak Baban; Jun Yao Liu; Xu Qin; Neal L Weintraub; Mahmood S Mozaffari
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

8.  The role of PD-1 in regulation of macrophage apoptosis and its subversion by Leishmania donovani.

Authors:  Shalini Roy; Purnima Gupta; Shreyasi Palit; Moumita Basu; Anindita Ukil; Pijush K Das
Journal:  Clin Transl Immunology       Date:  2017-05-05

Review 9.  First-line treatment of metastatic melanoma: role of nivolumab.

Authors:  Jeremy Force; April Ks Salama
Journal:  Immunotargets Ther       Date:  2017-02-13

10.  The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis.

Authors:  Katrin Neumann; Annett Ostmann; Philippe Christophe Breda; Aaron Ochel; Frank Tacke; Hans-Joachim Paust; Ulf Panzer; Gisa Tiegs
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.